查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495568

软雾吸入器市场 - 按产品类型（一次性、可重复使用）、年龄层（成人、儿童）、应用（气喘、慢性阻塞性肺病）、配销通路（医院药房、零售药房、线上药房）、最终用途与全球预测， 2024 - 2032

Soft Mist Inhalers Market - By Product Type (Disposable, Reusable), Age-Group (Adult, Pediatric), Application (Asthma, COPD), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End-Use & Global Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于气喘、慢性阻塞性肺病 (COPD) 和过敏性鼻炎等呼吸系统疾病盛行率不断上升，2024 年至 2032 年间，软雾吸入器市场规模将以 9.2% 的复合年增长率成长。根据世界卫生组织的数据，慢性阻塞性肺病 (COPD) 是一种常见的肺部疾病，它会导致呼吸困难，每年夺走超过 300 万人的生命。与传统的定量吸入器(MDI) 和干粉吸入器(DPI) 相比，软雾化器具有使用方便、连续给药以及降低手肺协调问题风险等优势，使其越来越受到患者的欢迎，尤其是老年人和老年人。

最近，製药公司越来越多地投资于研发活动，透过优化药物配方、设备设计和推进剂系统来提高软雾化器的有效性、安全性和效率。这些创新旨在透过促进医疗保健专业人员和患者采用软雾化器来提高患者的依从性，最大限度地减少副作用并最大限度地提高治疗效果。

整个产业分为产品类型、年龄层、应用、配销通路、最终用途和地区。

根据产品类型，一次性细分市场的软雾吸入器市场在2024 年至2032 年间将达到8.7% 的成长率。需求。这些吸入器还可以降低医疗机构中交叉污染和感染传播的风险，解决与病人安全和感染控制相关的问题。

预计从 2024 年到 2032 年，气喘应用的软雾吸入器市场复合年增长率将达到 9.4%。 全球气喘盛行率的不断上升导致对有效、方便的吸入疗法的需求更高。与定量吸入器 (MDI) 和干粉吸入器 (DPI) 等传统吸入装置相比，软雾吸入器具有多种优势，包括改善肺部沉积、减少手肺协调问题以及易于使用。这些特性使它们特别适合气喘患者，包括儿童和老年人。

由于城市化、污染和生活方式的改变，亚太地区软雾吸入器产业预计在 2024 年至 2032 年期间将以 9.9% 的复合年增长率快速成长。中国和印度等新兴经济体的医疗保健支出不断增加，医疗服务的可近性不断提高。医疗保健基础设施的快速进步，加上人们对呼吸系统健康和治疗选择的认识不断提高，将进一步推动区域市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 呼吸道疾病盛行率上升
      • 患者对吸入疗法的偏好激增
      • 对药物输送装置的需求不断增加
    • 产业陷阱与挑战
      • 高成本和替代产品的可用性
  • 成长潜力分析
  • 监管环境
  • 技术景观
  • 产品管道分析
  • 报销场景
  • 波特的分析
  • PESTEL分析
  • 未来市场趋势

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品类型，2021 - 2032 年

  • 主要趋势
  • 一次性的
  • 可重复使用的

第 6 章：市场估计与预测：按年龄划分，2021 - 2032

  • 主要趋势
  • 成人
  • 儿科

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 气喘
  • 慢性阻塞性肺病

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第 9 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院和诊所
  • 家庭护理设置
  • 其他最终用户

第 10 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋
    • 中东和非洲其他地区

第 11 章：公司简介

  • Aero Pump G.m.b.H
  • Boehringer Ingelheim
  • Changzhou DSB Medical Co., Ltd.
  • Merxin Ltd.
简介目录
Product Code: 8761

Soft mist inhalers market size will grow at 9.2% CAGR between 2024 and 2032, driven by the increasing prevalence of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. As per WHO, chronic obstructive pulmonary disease (COPD), a frequent lung ailment, led to breathing difficulties while claiming the lives of over 3 million people annually. Soft nebulizers provide advantages over traditional metered dose inhalers (MDIs) and dry powder inhalers (DPIs), including ease of use, continuous drug delivery, and reduced risk of hand-lung coordination problems, making them increasingly popular with patients, especially the old and children.

Lately, pharmaceutical companies are increasingly investing in R&D activities to improve the effectiveness, safety, and efficiency of soft nebulizers by optimizing drug formulations, device design and propellant systems. These innovations aim to improve patient compliance, minimize side effects and maximize treatment outcomes by promoting the adoption of soft nebulizers among healthcare professionals and patients.

The overall industry is classified into product type, age group, application, distribution channel, end-use, and region.

Based on product type, the soft mist inhalers market from the disposable segment will witness 8.7% growth rate between 2024 and 2032.Disposable inhalers provide convenience and portability while reducing the need for cleaning and maintenance of reusable devices. These inhalers also reduce the risk of cross-contamination and infection transmission in healthcare settings, addressing concerns related to patient safety and infection control.

Soft mist inhalers market from the asthma application is anticipated to witness 9.4% CAGR from 2024 to 2032. The increasing prevalence of asthma worldwide has led to the higher demand for effective and convenient inhalation therapies. Soft mist inhalers provide advantages over traditional inhalation devices, such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), including improved lung deposition, reduced hand-lung coordination issues, and ease of use. These properties are making them particularly suitable for asthma patients, including children and the elderly.

Asia Pacific soft mist inhalers industry is anticipated to grow at a significant pace at 9.9% CAGR over 2024-2032, attributed to urbanization, pollution, and changing lifestyles. There is rising healthcare expenditure and improving access to medical services in emerging economies like China and India. Rapid advancements in healthcare infrastructure, coupled with growing awareness about respiratory health and treatment options will further fuel the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of respiratory conditions
      • 3.2.1.2 Surge in patient preference for inhalation therapy
      • 3.2.1.3 Increasing demand for drug delivery devices
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost and availability of alternative products
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Product pipeline analysis
  • 3.7 Reimbursement scenario
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis
  • 3.10 Future market trends

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Disposable
  • 5.3 Reusable

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Adult
  • 6.3 Pediatric

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Asthma
  • 7.3 COPD

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospitals and clinics
  • 9.3 Homecare settings
  • 9.4 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
    • 10.5.4 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 South Africa
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Aero Pump G.m.b.H
  • 11.2 Boehringer Ingelheim
  • 11.3 Changzhou DSB Medical Co., Ltd.
  • 11.4 Merxin Ltd.